Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has shared an announcement.
NeuroScientific Biopharmaceuticals Ltd has initiated the transfer of its patented manufacturing process for mesenchymal stromal cells to Q-Gen Cell Therapeutics, a leading cell therapy contract manufacturer in Australia. This strategic partnership aims to scale the production of NeuroScientific’s StemSmart™ technology, which has shown promise in treating conditions like Crohn’s disease and graft versus host disease. The collaboration is expected to enhance the company’s manufacturing capabilities, enabling further clinical trials and commercial opportunities, thereby strengthening its position in the biotechnology industry.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited is a biotechnology company focused on developing novel therapeutics targeting immune-mediated inflammatory disorders. The company emphasizes modulating pathological immune responses in chronic and degenerative conditions where current treatments show limited efficacy. They employ advanced preclinical and translational strategies to develop first-in-class or best-in-class biologics addressing significant unmet clinical needs.
Average Trading Volume: 520,713
Technical Sentiment Signal: Buy
Current Market Cap: A$79.82M
See more insights into NSB stock on TipRanks’ Stock Analysis page.